Multiple Myeloma
Top Cited Papers
- 28 October 2004
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (18), 1860-1873
- https://doi.org/10.1056/nejmra041875
Abstract
Multiple myeloma, a plasma-cell neoplasm characterized by skeletal destruction, renal failure, anemia, and hypercalcemia, remains incurable. However, recent advances in its treatment, in particular, the use of thalidomide and such new drugs as bortezomib and CC-5013, are promising. This article discusses current therapy for multiple myeloma.Keywords
This publication has 90 references indexed in Scilit:
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple MyelomaMayo Clinic Proceedings, 2003
- Multiple Myeloma: How Far Have We Come?Mayo Clinic Proceedings, 2003
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990